ERBB2 and non-small cell lung carcinoma: The phase II DESTINY-Lung01 trial [18] demonstrated that T-DXd achieved an mPFS of 8.2 months and an mOS of 17.8 months in HER2-mutant NSCLC patients as a second-line and later treatment.